Vesicular stomatitis virus induces apoptosis in the Wong-Kilbourne derivative of the Chang conjunctival cell line

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 6, 2006, Pages 717-724

  Gallyas, Éva ^a   Seprényi, György ^a   Sonkoly, Eniko ^a   Mándi, Yvette ^a   Kemény, Lajos ^a   Megyeri, Klára ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Apoptosis; Bax; Bcl 2; Vesicular stomatitis virus; WK conjunctival cell line

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DEATH; CELL IMMORTALIZATION; CONJUNCTIVA TUMOR; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPY; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR CELL CULTURE; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS TITRATION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CONJUNCTIVAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPATHOGENIC EFFECT, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; PLAQUE ASSAY; PROTO-ONCOGENE PROTEINS C-BCL-2; VESICULAR STOMATITIS INDIANA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 33745241374     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0162-9     Document Type: Article

References (37)

1. Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN (2000) Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. J Virol 74:1513-1523
2. Balachandran S, Porosnicu M, Barber GN (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol 75:3474-3479
3. Balachandran S, Barber GN (2004) Defective translation control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51-65
4. Basti S, Macsai MS (2003) Ocular surface squamous neoplasia: A review. Cornea 22:687-704
5. Cao X, Deng X, May S (2003) Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and cathepsin-like protease may rapidly degrade p18 Bax. Blood 102:2605-2614
6. Cartron P-F, Oliver L, Juin P, Meflah K, Vallette FM (2004) The p18 truncated form of Bax behaves like a Bcl-2 homology domain 3-only protein. J Biol Chem 279:11503-11512
7. Debatin KM (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53:153-159
8. De Saint Jean M, Baudouin C, Di Nolfo M, Roman S, Lozato P, Warnet JM, Brignole F (2004) Comparison of morphological and functional characteristics of primary-cultured human conjunctival epithelium and of Wong-Kilbourne derivative of Chang conjunctival cell line. Exp Eye Res 78:257-274
9. Ebert O, Shinozaki K, Huang TG (2003) Oncolytic vesicular stomatitis virus for treatment of orthopic hepatocellular carcinoma in immune-competent rats. Cancer Res 63:3605-3611
10. Ebert O, Shinozaki K, Kournioti C, Park MS, García-Sastre A, Woo SL (2004) Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64:3265-3270
11. Fernandez M, Porosnicu M, Markovic D, Barber GN (2002) Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 76:895-904
12. Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SL (2003) Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immunocompetent mice. Mol Ther 8:434-440
13. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M (2000) Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 97:10872-10877
14. Kirn DH (2000) Replication-selective microbiological agents: Fighting cancer with targeted germ warfare. J Clin Invest 105:837-839
15. Kopecky SA, Willingham MC, Lyles DS (2001) Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 75:12169-12181
16. Kopecky SA, Lyles DS (2003) Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol 77:4658-4669
17. Kopecky SA, Lyles DS (2003) The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 77:5524-5528
18. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC (1994) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323-1336
19. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183-192
20. Letchworth GJ, Rodriguez LL, Del C, Barrera J (1999) Vesicular stomatitis. Vet J 157:239-260
21. Lichty BD, Power AT, Stojdl DF, Bell JC (2004) Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol Med 10:210-216
22. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC (2004) Vesicular stomatitis virus: A potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 15:821-831
23. Lyles DS (2000) Cytopathogenesis and inhibition of host gene expression by RNA viruses. Microbiol Mol Biol Rev 64:709-724
24. Obuchi M, Fernandez M, Barber GN (2003) Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J.Virol 77:8843-8856
25. Ohta K, Iwai K, Kasahara Y, Taniguchi N, Krajewski S, Reed JC, Miyawaki T (1995) Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol 7:1817-1825
26. Petersen JM, Her LS, Varvel V, Lund E, Dahlberg JE (2000) The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complex. Mol Cell Biol 20:8590-8601
27. Re GG, Hazen-Martin DJ, El Bahtimi R, Brownlee NA, Willingham MC, Garvin AJ (1999) Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases. Int J Cancer 84:192-200
28. Ring CJA (2002) Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83:491-502
29. Rodriguez LL, Pauszek SJ, Bunch TA, Schumann KR (2002) Full-length genome analysis of natural isolates of vesicular stomatitis virus (Indiana 1 serotype) from North, Central and South America. J Gen Virol 83:2475-2483
30. Rose JK, Whitt MA (2001) Rhabdoviridae: The viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1221-1242
31. Shields CL, Shields JA (2004) Tumors of the conjunctiva and cornea. Surv Ophthalmol 49:3-24
32. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL (2004) Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9:368-376
33. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC (2000) Exploiting tumor-specific defects in the interferon pathway with previously unknown oncolytic virus. Nat Med 6:821-825
34. Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC (2000) The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 74:9580-9585
35. Stojdl DF, Lichty BD, tenOver BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell 4:263-275
36. Verma IM, Weitzman MD (2005) Gene therapy: Twenty-first century medicine. Annu Rev Biochem 74:711-738
37. Wilson MW, Czechonska G, Finger PT, Rausen A, Hooper ME, Haik BG (2001) Chemotherapy for eye cancer. Surv Ophthalmol 45:416-444